Beginning with the acquisition of Dabur Pharma Limited by Fresenius Kabi Singapore Pte Limited (part of Fresenius Kabi Group) in 2008, the Company has come a long way and established itself as a leading player in the field of generic oncology products and thrives for research and development and manufacture of life-saving medicines for cancer therapy.  

2008

Fresenius Kabi Singapore Pte Limited (a part of Fresenius Kabi Group) acquired Dabur Pharma Limited from its Promoters, Burman Families.

2009

Name of the Company changed as Fresenius Kabi Oncology Limited, marking the complete integration of the acquired Company with  Fresenius Kabi.

2010

Opening of newly developed Research & Development Center and Corporate Office at Gurgaon, Haryana. 

2011

Facility upgradation for APIs and Intermediates - 10DAB, MTSC-9 and MS block for Irinotecan (Int) start-up at Production Unit in Kalyani, West Bengal.

2012

Second filling line for the sterile injections added as part of capacity enhancement at the Production Unit in Kishanpura, Nalagarh, Himachal Pradesh.

2016

Microbiological testing laboratory revamped as part of continuous quality improvement at Production Unit in Kishanpura, Nalagarh, Himachal Pradesh.

2019

Start-up of New Excipient block for Cremophor and Polysorbate manufacturing at Production Unit in Kalyani, West Bengal.

Consolidation of Finished Dosage Formulations manufacturing operations from multiple Units in Baddi into the Unit located at Kishanpura in Nalagarh, Himachal Pradesh.  

2021

Project approved for addition of capability in Kishanpura, Nalagarh Unit for Anti-infective and general products (Injection) Portfolio besides the existing facility for manufacture of the Oncology products.